Concepedia

Jeffrey D. Kent

JD

36

Publications

9.3K

Citations

23

H-Index

1980

Active since

Affiliations

Horizon Therapeutics (United States)(Current)

University of Illinois Chicago

Abbott Fund

University of Chicago

University of Calgary

Jeffrey D. Kent is an author at Horizon Therapeutics (United States) specializing in medicine, physiology, and pharmacology.

Top concepts

Publications per year

1980–2019

36

Publications

36

Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis

Fred E. Silverstein, Gerald A. Faich, Jay L. Goldstein et al. · JAMA · 2000 · 3.2K citations

Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

Jean–Frédéric Colombel, William J. Sandborn, Paul Rutgeerts et al. · Gastroenterology · 2006 · 2.2K citations

, , +7

Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

William J. Sandborn, S. B. Hanauer, P. Rutgeerts et al. · Gut · 2007 · 1K citations · Full text

Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab

William J. Sandborn, Paul Rutgeerts, Robert Enns et al. · Annals of Internal Medicine · 2007 · 955 citations

Adalimumab for the treatment of fistulas in patients with Crohn’s disease

J F Colombel, David A. Schwartz, William J. Sandborn et al. · Gut · 2009 · 351 citations · Full text

Rows per page

1–5 of 36